Navigation Links
Dengue Fever Vaccine Shows Some Promise in Trial
Date:7/11/2014

By
HealthDay Reporter

THURSDAY, July 10, 2014 (HealthDay News) -- A potential vaccine to protect children from the worldwide scourge of dengue fever was somewhat successful in a trial among Asian children.

While the vaccine only prevented dengue fever in 56 percent of the 10,000 kids who got the full series of three shots, it protected more than 88 percent of them from severe disease. In the worst-case scenarios, dengue fever can lead to hospitalization, and sometimes death.

"This vaccine has already proven to be safe," said Tyler Sharp, an epidemiologist in the dengue branch of the U.S. Centers for Disease Control and Prevention, who had no role in the trial. "We know that this vaccine does not lead to a risk of developing severe dengue -- that is a huge step forward."

However, "the 56 percent is not as high as we would like to see it. It's still a big step forward, but we have a way to go before we get a vaccine that is both safe and as efficacious as we would need it to be," Sharp added.

Of the 400 million people infected worldwide every year, about half have mild symptoms such as fever and body pain that goes away in a couple of days, Sharp said. But the other half have intense pain, severe headaches and high fever, and some may have minor bleeding under the skin, or from the gums or nose, he added. There is no treatment for dengue.

In the United States, dengue is endemic in Puerto Rico, the U.S. Virgin Islands and the U.S. territories in the Pacific Ocean, Sharp said. Although isolated cases of the mosquito-borne disease have cropped up in Florida and Texas in recent years, Sharp said he did not expect the disease to gain a foothold in the continental United States.

Dr. Annelies Wilder-Smith, a professor of infectious diseases research at the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore, stressed that a more effective vaccine is needed.

"Of course, our desire is to have a vaccine efficacy of above 90 percent," she noted.

Wilder-Smith, who authored an accompanying journal editorial, noted that other dengue vaccines are being tested, but it will take several years before those vaccines reach phase 3 trials.

"For the time being, this is the best and the only one we have," she said of the current vaccine, known as CYD-TDV.

The report, from scientists at the Research Institute for Tropical Medicine in the Philippines, was published online July 11 in The Lancet.

Dr. Marcelo Laufer, an infectious diseases specialist at Miami Children's Hospital, said he was "not impressed" by the efficacy of the vaccine.

Laufer also noted that the vaccine needs to be tested in other areas, particularly in Latin America, and that patients need to be followed for at least five years.

"I am curious to see how the vaccine would work in different populations," he said.

The trial, funded by vaccine maker Sanofi Pasteur, focused on children aged 2 to 14. They were randomly assigned to receive three injections of the CYD-TDV vaccine or a placebo vaccine.

After the first vaccination, the second was given six months later and the third six months after that. The children were followed for up to two years.

More than 28 days after the third vaccination, 117 children who received the vaccine developed dengue, compared with 133 who were given placebo. That works out to a vaccine effectiveness rate of 56.5 percent, the researchers noted.

In addition, after three doses, the vaccine was 88.5 percent effective against severe disease, which often leads to hospitalization for over 500,000 people -- mostly children -- every year.

"One of the difficulties in making a dengue vaccine is that you have to cover for four different viruses at the same time," Sharp explained. "If you are not able to do that, you risk increasing the chances of developing severe dengue."

The vaccine wasn't equally effective against all four dengue viruses. It was only 35 percent effective against type 2, more than 75 percent effective against types 3 and 4, and 50 percent effective against type 1.

The vaccine was well tolerated, the researchers reported. A total of 402 serious adverse events were reported in the vaccine group and 245 were reported in the placebo group.

More information

For more on dengue fever, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: Tyler Sharp, Ph.D., epidemiologist, dengue branch, U.S. Centers for Disease Control and Prevention; Annelies Wilder-Smith, M.D., Ph.D., professor, infectious diseases research, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Marcelo Laufer, M.D., infectious diseases specialist, Miami Children's Hospital, Miami, Fla.; July 11, 2014, The Lancet, online


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. CU researchers discover target for treating dengue fever
2. Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
3. Second largest research award at Notre Dame fights malaria and dengue fever
4. Texas-Based Agency, Weiser Insurance, Warns Houston Residents of the Increased Danger of Contracting Dengue Fever This Fall
5. InBios' Dengue IgM ELISA Continues to Prove Fast and Effective for Presumptive Diagnosis of Dengue Virus Infection
6. New findings could influence the development of therapies to treat dengue disease
7. NTU designs social media and web system that can predict dengue hotspots
8. Mast cells give clues in diagnosis, treatment of dengue
9. Warning system predicts outbreaks of dengue fever
10. La Jolla Institutes surprising finding could alter the face of dengue vaccine development
11. Global burden of dengue is triple current estimates
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dengue Fever Vaccine Shows Some Promise in Trial
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which the ... on the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, ...
(Date:5/24/2017)... ... , ... Rob Lowe is a sought after actor, and also serves as ... public important topics from all aspects of life, and a new segment is being ... and ankles. , Podiatry is essential to people’s overall well-being, and if viewers have ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/3/2017)... N.J. , May 3, 2017  Getinge, ... that contribute to quality enhancement and cost efficiency ... from a study of contemporary practice demonstrating that ... first-line therapy for critically ill patients. The single-center, ... Company,s newer large volume MEGA ® 50cc ...
Breaking Medicine Technology: